| 000 | 00986 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250514005123.0 | ||
| 264 | 0 | _c20010927 | |
| 008 | 200109s 0 0 eng d | ||
| 022 | _a1368-5031 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHanefeld, M | |
| 245 | 0 | 0 |
_aClinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor. _h[electronic resource] |
| 260 |
_bInternational journal of clinical practice _c |
||
| 300 |
_a399-405 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aCoronary Disease _xprevention & control |
| 650 | 0 | 4 |
_aFluorobenzenes _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aHyperlipidemias _xdrug therapy |
| 650 | 0 | 4 | _aPyrimidines |
| 650 | 0 | 4 | _aRosuvastatin Calcium |
| 650 | 0 | 4 | _aSulfonamides |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tInternational journal of clinical practice _gvol. 55 _gno. 6 _gp. 399-405 |
|
| 999 |
_c11426426 _d11426426 |
||